Travis Murdoch, HI-Bio CEO
November 1, 2022 06:14 AM EDTUpdated 12:40 PM
Financing
Startups

That se­cre­tive ARCH biotech with two an­ti­bod­ies from Mor­phoSys? It’s now got $120M

Lei Lei Wu

News Reporter

In June, HI-Bio, short for Hu­man Im­munol­o­gy Bio­sciences, li­censed two can­di­dates from Ger­man biotech Mor­phoSys — felzartam­ab for two au­toan­ti­body kid­ney dis­eases, and HIB210, which goes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times